Narrative review highlights how SGLT2i and GLP-1 RAs improve kidney function and cardiovascular outcomes in CKD patients, suggesting integrated care approaches.
Key Points
SGLT2i reduce the risk of kidney failure by 25–40% in both diabetic and non-diabetic CKD populations.
GLP-1 RAs slow renal function decline and enhance cardiovascular health through direct protective mechanisms.
Combination use of SGLT2i and GLP-1 RAs may further enhance organ protection, addressing multiple disease pathways.
Understanding the mechanisms of these therapies can inform better management strategies for CKD and related conditions.